Soligenix, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SNGX, updated each market day.
SNGX AI Sentiment
AI predicts Soligenix, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Soligenix, Inc. Common Stock
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Sector
Exchange
Market Cap
$14,119,328
Cap Tier
Employees
14
Headquarters
PRINCETON, NJ
Listed Since
April 5, 1994
Website
SNGX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SNGX Volatility
Soligenix, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
